Literature DB >> 25024392

T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association.

D Huw Davies1, Sookhee Chun2, Gary Hermanson3, Jo Anne Tucker4, Aarti Jain2, Rie Nakajima2, Jozelyn Pablo5, Philip L Felgner2, Xiaowu Liang3.   

Abstract

Vaccinia virus (VACV) is a useful model system for understanding the immune response to a complex pathogen. Proteome-wide Ab profiling studies reveal the humoral response to be strongly biased toward virion-associated Ags, and several membrane proteins induce Ab-mediated protection against VACV challenge in mice. Some studies have indicated that the CD4 response is also skewed toward proteins with virion association, whereas the CD8 response is more biased toward proteins with early expression. In this study, we have leveraged a VACV strain Western Reserve (VACV-WR) plasmid expression library, produced previously for proteome microarrays for Ab profiling, to make a solubilized full VACV-WR proteome for T cell Ag profiling. Splenocytes from VACV-WR-infected mice were assayed without prior expansion against the soluble proteome in assays for Th1 and Th2 signature cytokines. The response to infection was polarized toward a Th1 response, with the distribution of reactive T cell Ags comprising both early and late VACV proteins. Interestingly, the proportions of different functional subsets were similar to that present in the whole proteome. In contrast, the targets of Abs from the same mice were enriched for membrane and other virion components, as described previously. We conclude that a "nonbiasing" approach to T cell Ag discovery reveals a T cell Ag profile in VACV that is broader and less skewed to virion association than the Ab profile. The T cell Ag mapping method developed in the present study should be applicable to other organisms where expressible "ORFeome" libraries are also available, and it is readily scalable for larger pathogens.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25024392      PMCID: PMC4119580          DOI: 10.4049/jimmunol.1400663

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  87 in total

1.  Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.

Authors:  Edward Bell; Mohammad Shamim; J Charles Whitbeck; Georgia Sfyroera; John D Lambris; Stuart N Isaacs
Journal:  Virology       Date:  2004-08-01       Impact factor: 3.616

2.  Protein composition of the vaccinia virus mature virion.

Authors:  Wolfgang Resch; Kim K Hixson; Ronald J Moore; Mary S Lipton; Bernard Moss
Journal:  Virology       Date:  2006-09-26       Impact factor: 3.616

Review 3.  Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource.

Authors:  Yohan Kim; Alessandro Sette; Bjoern Peters
Journal:  J Immunol Methods       Date:  2010-10-31       Impact factor: 2.303

4.  Obligatory requirement for antibody in recovery from a primary poxvirus infection.

Authors:  Geeta Chaudhri; Vijay Panchanathan; Horst Bluethmann; Gunasegaran Karupiah
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Identification of a vaccinia virus penetration protein.

Authors:  Y Ichihashi; T Takahashi; M Oie
Journal:  Virology       Date:  1994-08-01       Impact factor: 3.616

6.  A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies.

Authors:  E J Wolffe; S Vijaya; B Moss
Journal:  Virology       Date:  1995-08-01       Impact factor: 3.616

7.  Immunome-derived vaccines.

Authors:  Anne S De Groot
Journal:  Expert Opin Biol Ther       Date:  2004-06       Impact factor: 4.388

8.  In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes.

Authors:  Leonard Moise; Julie A McMurry; Soren Buus; Sharon Frey; William D Martin; Anne S De Groot
Journal:  Vaccine       Date:  2009-06-24       Impact factor: 3.641

9.  ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans.

Authors:  Lichen Jing; Stella Mayo McCaughey; D Huw Davies; Tiana M Chong; Phillip L Felgner; Stephen C De Rosa; Christopher B Wilson; David M Koelle
Journal:  J Immunol Methods       Date:  2009-06-09       Impact factor: 2.303

Review 10.  Revealing the role of CD4(+) T cells in viral immunity.

Authors:  Andrea J Sant; Andrew McMichael
Journal:  J Exp Med       Date:  2012-07-30       Impact factor: 14.307

View more
  3 in total

1.  Identification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening.

Authors:  Kaustuv Nayak; Lichen Jing; Ronnie M Russell; D Huw Davies; Gary Hermanson; Douglas M Molina; Xiaowu Liang; David R Sherman; William W Kwok; Junbao Yang; John Kenneth; Syed F Ahamed; Anmol Chandele; Kaja Murali-Krishna; David M Koelle
Journal:  Tuberculosis (Edinb)       Date:  2015-03-27       Impact factor: 3.131

2.  Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants.

Authors:  Jenny E Hernandez-Davies; Emmanuel P Dollinger; Egest J Pone; Jiin Felgner; Li Liang; Shirin Strohmeier; Sharon Jan; Tyler J Albin; Aarti Jain; Rie Nakajima; Algimantas Jasinskas; Florian Krammer; Aaron Esser-Kahn; Philip L Felgner; Qing Nie; D Huw Davies
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

3.  Of monkeys and men: immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates.

Authors:  Mark S Pearson; Luke Becker; Patrick Driguez; Neil D Young; Soraya Gaze; Tiago Mendes; Xiao-Hong Li; Denise L Doolan; Nicholas Midzi; Takafira Mduluza; Donald P McManus; R Alan Wilson; Jeffrey M Bethony; Norman Nausch; Francisca Mutapi; Philip L Felgner; Alex Loukas
Journal:  Front Immunol       Date:  2015-05-05       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.